Received Aug 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | Z004455 | — |
No adverse event; MVCC agent transferred medical assistant who reported VARIVAX involved in temperature excursion has been administered to multiple patients since being involved in the excursion. Caller provided patient information for each dose administered, also see; This spontaneous report was received from an Other health professional and refers to a patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. It was reported that on 07-Jul-2025, the Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) lot #Z004455, expiration date: 13-Feb-2027 was involved in temperature excursion of 36.5F for the time frame of 2 hours 21 minutes. On an unknown date in July 2025, the patient was vaccinated with the first dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) lot #Z004455, expiration date: 13-Feb-2027 (dose, units and route of administration were not reported), which was reconstituted with sterile diluent (lot# and expiration date were not reported) and administered for prophylaxis. There was no additional adverse event. Lot # (regarding sterile diluent) is being requested and will be submitted if received.
sterile diluent